Surpassing conventional therapies: The role of biologic therapy

Journal of Pediatric Gastroenterology and Nutrition

Volumn 33, Issue SUPPL. 1, 2001, Pages

  Baldassano, R N ^a  

^a CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALICAFORSEN; ALPHA TOCOPHEROL; ANTISENSE OLIGONUCLEOTIDE; AZATHIOPRINE; ETANERCEPT; GLUCOCORTICOID; IMMUNOMODULATING AGENT; INFLIXIMAB; INTERCELLULAR ADHESION MOLECULE 1; MERCAPTOPURINE; METHOTREXATE; OMEGA 3 FATTY ACID; PROBIOTIC AGENT; RECOMBINANT INTERLEUKIN 10; RECOMBINANT INTERLEUKIN 11; SHORT CHAIN FATTY ACID; TUMOR NECROSIS FACTOR ALPHA ANTIBODY;

CLINICAL FEATURE; CLINICAL TRIAL; CONFERENCE PAPER; CROHN DISEASE; DISEASE COURSE; GROWTH RETARDATION; HEPATITIS; HUMAN; IMMUNOMODULATION; LEUKOPENIA; PANCREATITIS; PRIORITY JOURNAL; REMISSION;

EID: 0034800239     PISSN: 02772116     EISSN: None     Source Type: Journal    
DOI: 10.1097/00005176-200109001-00004     Document Type: Conference Paper

References (27)

1. Prolonged duration of response to infliximab in early but not late pediatric Crohn's disease
2. Use of infliximab in the treatment of Crohn's disease in children and adolescents
3. A multicenter study of infliximab (anti-TNF-alpha antibody) in the treatment of children with active Crohn's disease
4. Biologic therapy for inflammatory bowel disease
5. Infliximab: A novel chimeric monoclonal antibody for the treatment of Crohn's disease
6. Genetic and spontaneous models of inflammatory bowel disease in rodents: Evidence for abnormalities in mucosal immune regulation
7. Tumour necrosis factor alpha in stool as a marker of intestinal inflammation
8. Cytokines in stools of children with inflammatory bowel disease or infective diarrhoea
9. Enhanced secretion of tumour necrosis factor-alpha, IL-6, and IL-1 beta by isolated lamina propria mononuclear cells from patients with ulcerative colitis and Crohn's disease
10. Construction and initial characterization of a mouse-human chimeric anti-TNF antibody
11. Chimeric anti-TNF-α monoclonal antibody cA2 binds recombinant transmembrane TNF-α and activates immune effector functions
12. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor α for Crohn's disease
13. Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn's disease
14. Infliximab for the treatment of fistulas in patients with Crohn's disease
15. Long term safety of infliximab
16. A randomized controlled trial of CDP-571, a humanized antibody to TNFA, in moderately to severely active Crohn's disease
17. A randomized, double-blind, placebo-controlled, multi-center trial of the engineered human antibody to TNF (CDP-571) for steroid sparing and maintenance of remission in patients with steroid-dependent Crohn's disease
18. Recombinant soluble tumor necrosis factor receptor (p80) fusion protein: Toxicity and dose finding trial in rheumatoid arthritis
19. Etanercept (TNF receptor fusion protein, Enbrel®) is effective and well tolerated in active refractory Crohn's disease: Results of a single center pilot trial
20. Multiple doses of intravenous interleukin 10 in steroid-refractory Crohn's disease
21. Recombinant human interleukin 10 in the treatment of patients with mild to moderately active Crohn's disease. The Interleukin 10 Inflammatory Bowel Disease Cooperative Study Group
22. Safety and efficacy of recombinant human interleukin 10 in chronic active Crohn's disease. Crohn's Disease IL-10 Cooperative Study Group
23. Interleukin 11: Review of molecular, cell biology, and clinical use
24. A randomized, double-masked, placebo-controlled study of recombinant human interleukin eleven (RHIL-11) in Crohn's disease subjects not receiving prednisone
25. Tumor necrosis factor and Crohn's disease
26. Gene therapy '97. Message therapy: Gene therapy that targets mRNA sequence and stability
27. A placebo-controlled trial of ICAM-I antisense oligonucleotide in the treatment of Crohn's disease